Relatedly, silencing SST interneuron inhibition led to depression symptoms [15], and novel therapeutic compounds acting via positive allosteric modulation of alpha-5-GABA-A (α5-GABAA) receptors targeted by SST interneurons resulted in pro-cognitive and anxiolytic effects [15,21]. The gene discussed is SST; the disease is major depressive disorder.